Notes

Derotational distal femoral osteotomy yields satisfactory medical outcomes in pathological femoral rotation together with unsuccessful inside patellofemoral tendon remodeling.
Results CECT enabled the identification of additional extranodal lesions (hepatic, muscular and gastric) in only 3 staging group cases (3.5%), indicating different stages as compared to UECT, whereas there was absolute agreement between CECT and UECT in terms of treatment response assessment. The added diagnostic value of CECT was lower than the established threshold for clinical relevance (15%). Mc Nemar's test indicated no statistical significance in either group. see more The incidental findings detected by CECT but not UECT were important for clinical management, but not sufficient to alter lymphoma treatment strategy. Conclusion According to our results, it might be possible to exclude CECT examination of 18FDG-avid lymphoma from staging and treatment response assessment, with the consequent advantages of reducing radiation exposure and potential contrast-related risks.Purpose The aim of this study was to assess a) the impact of forced diuresis with early furosemide injection on the detection rate of local recurrence (LR) in prostate cancer (PC) patients with biochemical recurrence (BR) referred for 68Ga-labelled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (68Ga-PSMA-11) Positron Emission Tomography/Computed Tomography (PET/CT) and b) whether intravenous administration of furosemide shortly after tracer injection increases renal wash-out of 68Ga-PSMA-11 before it binds to the PSMA-receptor with possible influence on biodistribution and intensity of tracer uptake in organs with physiologic tracer accumulation. Materials and Methods In a retrospective analysis two different groups with 220 prostate cancer patients each, referred for 68Ga-PSMA-11 PET/CT because of biochemical recurrence after primary therapy, were compared patients of group one (median prostate specific antigen (PSA) 1.30 ng/ml) receiving no preparation prior to imaging, whereas patients in group two (median PSA 0.82 ng/ml)up receiving furosemide. Conclusion Injection of 20 mg furosemide at the timepoint of radiotracer administration significantly increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence referred for 68Ga-PSMA-11 PET/CT. As intensity of 68Ga-PSMA-11-uptake in organs with physiologic uptake is not significantly reduced, a negative impact of early furosemide injection on targeting properties and biodistribution of 68Ga-PSMA-11 seems unlikely.To date, three fluorine-18 labelled tracers have been approved for assessing cerebral amyloid plaques pathology to assist in the diagnosis of Alzheimer's Disease (AD). Although scanning protocols are relatively similar across tracers, FDA/EMA approved visual rating guidelines to render scans as positive or negative differ between the three tracers. The purpose of the present study was to assess the comparability of visual rating results when applying the three different FDA/EMA approved visual interpretation protocols to all three amyloid tracers both for experts and non-experts. Methods In an international multicentre approach, both experts (N = 4) and non-experts (N = 3) rated scans acquired with fluorine-18 labelled florbetaben, florbetapir and flutemetamol. Scans obtained with each tracer were presented for reading according to all three approved visual rating protocols. In a randomized order, every single scan was rated by each reader according to all three protocols, resulting in a total of more than 70ter agreement despite applying different visual rating protocols for all fluorine-18 labelled amyloid tracers, suggesting sufficient potiential for a standardization for visual assessment of cerebral amyloid plaques. Non-experts, however, may need extensive training on reading fluorine-18 labelled amyloid scans and may particularly benefit from a universal readout to ensure comparability across visual evaluation strategies.Purpose Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands are a new class of 18F-labeled PSMA-targeting agents. 18F-rhPSMA-7.3 is a lead compound which is currently under investigation in two multicenter phase III trials for PET-imaging. Here, we report the first retrospective data on its detection efficacy and potential impact on clinical management in a homogeneous cohort of patients with biochemical recurrence after radical prostatectomy, and prior to any salvage therapy. Methods 242 patients (median [range] PSA, 0.60 [0.2-60.8] ng/mL) who underwent 18F-rhPSMA-7.3 PET/CT were retrospectively selected from the institutions' database. Images were re-read by an experienced nuclear medicine physician. Lesion detection rates were stratified by PSA. Further, potential management before and after PET was assessed by an interdisciplinary simulated tumor board and categorized (major vs. minor vs. no therapeutic change). The distribution of management change identified in each PSA subgroup was determinPSMA-7.3 PET offers high detection efficacy in patients with biochemical recurrence after radical prostatectomy, and prior to potential salvage therapy, and results in a potential change in treatment plans in nearly 2/3 of patients. Keywords Biochemical recurrence; hybrid imaging; positron emission tomography; prostate cancer; prostate-specific membrane antigen.Pancreatic cancer (PC) remains the 4th leading cause of cancer death; therefore, there is a clinically unmet need for novel therapeutics and diagnostic markers to treat this devastating disease. Physicians often rely on biopsy or CT for diagnosis, but more specific protein biomarkers are highly desired to assess the stage and severity of PC in a noninvasive manner. Serum biomarkers such as CA19.9 are of particular interest as they are commonly elevated in PC but have exhibited suboptimal performance in the clinic. MUC5AC has emerged as a useful serum biomarker that is specific for PC vs. inflammation. We developed RA96, an anti-MUC5AC antibody, to gauge its utility in PC diagnosis through immunohistochemical (IHC) analysis and whole-body PET in PC. Methods In this study, extensive biochemical characterization determined MUC5AC as the antigen for RA96. We then determined the utility of RA96 for MUC5AC IHC on clinical PC and pre-clinical PC. Finally, we radiolabeled RA96 with zirconium-89 to assess its application as a whole-body PET radiotracer for MUC5AC quantification in PC.
Here's my website: https://www.selleckchem.com/products/pf-03084014-pf-3084014.html